Magid received his PhD from the University of Pennsylvania in 1979. After an NIH post doctoral appointment at Temple University, he joined Wyeth in 1982 as a Senior Scientist. He advanced through various positions to become Senior VP and Head of Chemical and Screening Sciences. In 2008, after a long and productive career at Wyeth he joined the faculty at Temple University in Philadelphia in his current position as the Associate Dean for Research, Professor of Medicinal Chemistry and the Director of the Moulder Center for Drug Discovery Research (CDDR) at Temple’s School of Pharmacy.

Magid is a highly accomplished world-class scientist with over 27 years career mostly in Drug Discovery and Development that led to the identification and advancement of several clinical candidates in many therapeutic areas. He is credited with the discovery of six marketed drugs: Effexor®, Sonata®, Mylotarg™, Tygacil®, Bazedoxifene, and Temsirolimus. Magid holds a very impressive scientific track record that includes 87 peer-reviewed scientific publications, more than 120 presentations and invited lectures, 99 issued US patents and over 300 patents worldwide. He served on the Editorial and Scientific Advisory Boards of many journals and held several academic appointments. He has established five Wyeth-sponsored lectureships with Princeton, Penn, MIT, Columbia and Douglass College. His outstanding scientific achievements were recognized by many local and national awards and honors including (but not limited to) the 1997 ACS-Philadelphia Section Award, 2001 Philadelphia Organic Chemists Club Award, the 2008 ACS-Alfred Burger Award in Medicinal Chemistry, the 2008 Induction to Medicinal Chemistry Hall of Fame by the Division of Medicinal Chemistry of the ACS, the 2008 ACS Heroes of Chemistry Award and he was selected among “NJ’s Top 10 Scientists” by the New Jersey Business Magazine, December 2008 issue.

Magid is an outstanding manager of chemical research who was recognized nationally by the prestigious Earle B. Barnes Award for Leadership in Chemical Research Management in 2001. As the head of the discovery group at Wyeth he established a highly productive and innovative Medicinal Chemistry Department that delivered novel clinical candidates. Magid believes strongly in the role of science and scientific excellence in advancing pharmaceutical business; therefore, he has fostered a highly creative research environment to encourage the active involvement of his team members in the scientific community through publications, presentations and active participation in scientific meetings. In his current position at Temple University he is responsible for directing research efforts of a multidisciplinary team focusing on the design and synthesis of small molecule therapeutics in multiple disease areas.

Dr. Abou-Gharbia has been an active member of the ACS for over 35 years. He is also a Fellow of the Royal Society of Chemistry, Member of Society for Neuroscience and a Member of the New York Academy of Sciences.